Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Ahmad, Faiz ^a   Mani, Jiju ^a,b   Kumar, Pawan ^a   Haridas, Seenu ^a,c   Upadhyay, Pramod ^a   Bhaskar, Sangeeta ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SIZE; CELL FRACTIONATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; IMMUNOSTIMULATION; LOW DRUG DOSE; LYMPH NODE; LYMPHATIC DRAINAGE; LYMPHOCYTIC INFILTRATION; MELANOMA; MONOTHERAPY; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM INDICUS PRANII; NONHUMAN; OPTIMAL DRUG DOSE; PHENOTYPE; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SPLEEN; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NATURAL KILLER CELL; TUMOR CELL LINE;

ANIMALIA; MUS; MYCOBACTERIUM;

ANIMALS; CELL LINE, TUMOR; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MELANOMA; MICE; MICE, INBRED C57BL; MYCOBACTERIUM; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 80053592395     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025424     Document Type: Article

References (32)

1. Jarnicki AG, Lysaght J, Todryk S, Mills KH, (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177: 896-904.
2. Park SH, Kyin T, Bendelac A, Carnaud C, (2003) The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170: 1197-1201.
3. Baxevanis CN, Gritzapis AD, Papamichail M, (2003) In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol 171: 2953-2959.
4. Alexandroff AB, Jackson AM, O'Donnell MA, James K, (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689-1694.
5. Hayashi A, Doi O, Azuma I, Toyoshima K, (1998) Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc Japn Acad 74: 50-55.
6. Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B, et al. (2010) Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 17: 21.
7. Stanford JL, Stanford CA, O'Brien ME, Grange JM, (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44: 224-227.
8. Talwar GP, Zaheer SA, Mukherjee R, Walia R, Misra RS, et al. (1990) Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients. Vaccine 8: 121-129.
9. Saini V, Raghuvanshi S, Talwar GP, Ahmed N, Khurana JP, et al. (2009) Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PLoS One 4: e6263.
10. Cheadle EJ, O'Donnell D, Selby PJ, Jackson AM, (2005) Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun 73: 784-794.
11. Gupta A, Geetha N, Mani J, Upadhyay P, Bhaskar S, et al. (2009) Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immun 77: 223-231.
12. Chaudhuri P, Mukhopadhyay S, (2003) Bladder preserving approach for muscle invasive bladder cancer-role of mycobacterium w. J Indian Med Assoc 101: 559-560.
13. Sur PK, Dastidar AG, (2003) Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer). J Indian Med Assoc 101: 118 120.
14. Clevenger CV, Shankey TV, (2001) Preparation of cells and reagents for flow cytometry. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current Protocols in Immunology John Wiley and Sons, New York pp. 5.3.1-5.2.24.
15. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, et al. (2009) Improving the efficacy of cancer immunotherapy. Eur J Cancer 45: 1424-1431.
16. Dalgleish AG, Whelan MA, (2006) Cancer vaccines as a therapeutic modality: The long trek. Cancer Immunol Immunother 55: 1025-1032.
17. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, et al. (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205-1209.
18. Malmstrom P, (2000) Improved patient outcomes with BCG immunotherapy vs. chemotherapy- Swedish and worldwide experience. Eur Urol 37 (Suppl 1): 16-20.
19. Sylvester RJ, van der MEIJDEN AP, Lamm DL, (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970.
20. Luo Y, Chen X, Szilvasi A, O'Donnell MA, (2000) Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity. Mol Immunol 37: 527-536.
21. Daffe M, Draper P, (1998) The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 39: 131-203.
22. Laneelle G, Daffe M, (1991) Mycobacterial cell wall and pathogenicity: a lipodologist's view. Res Microbiol 142: 433-437.
23. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, et al. (2000) Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13: 265-276.
24. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, et al. (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88: 577-583.
25. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, et al. (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35: 23-28.
26. Zou W, (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
27. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173: 1444-1453.
28. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
29. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A, (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32: 3267-3275.
30. Johns DG, Webb RC, (1998) TNF-alpha-induced endothelium-independent vasodilation: a role for phospholipase A2-dependent ceramide signaling. Am J Physiol 275: H1592-H1598.
31. Patel N, Trapathi SB, (2003) Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. J Indian Med Assoc 101: 680 682.
32. Katoch K, Singh P, Adhikari T, Benara SK, Singh HB, et al. (2008) Potential of M.w as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 26: 1228-1234.